Gabriela Dumachita Sargu

Dr. Gabriela Dumachita Sargu

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
CFCristina Ozana Furnica
Cristina Ozana Furnica
RCRaluca Ozana Chistol
Raluca Ozana Chistol
DCDragos Andrei Chiran
Dragos Andrei Chiran
CSCristinel Ionel Stan
Cristinel Ionel Stan
GSGabriela Dumachita Sargu
Gabriela Dumachita Sargu
GTGrigore Tinica
Grigore Tinica
Background: The influence of the early COVID-19 pandemic on non-COVID-19 emergencies is uncertain. We conducted a systematic review and a meta-analysis to evaluate the impact of the first months of the COVID-19 pandemic on the presentation, management, and prognosis of patients presenting with ST-segment elevation myocardial infarction (STEMI). Methods: We searched the PubMed, Scopus, and Embase databases from January to August 2020. A meta-analysis of studies comparing the profile, STEMI severity at presentation, reperfusion delay, and in-hospital mortality for patients presenting before and during the early COVID-19 pandemic was conducted. Fifteen cross-sectional observational studies including 20,528 STEMI patients from the pre-COVID period and 2190 patients diagnosed and treated during the first months of the COVID-19 pandemic met the inclusion criteria. Results: Patients presenting with STEMI during the pandemic were younger and had a higher comorbidity burden. The time interval between symptoms and first medical contact increased from 93.22 ± 137.37 min to 142 ± 281.60 min (p < 0.001). Door-to-balloon time did not differ significantly between the two periods (p = 0.293). The pooled odds ratio (OR) for low left ventricular ejection fraction at presentation during the pandemic was 2.24 (95% confidence interval (CI) 1.54–3.26) and for a presentation delay >24 h was 2.9 (95% CI 1.54–5.45) relative to before the pandemic. In-hospital mortality did not increase significantly during the outbreak (p = 0.97). Conclusion: During the first months of the COVID-19 pandemic, patients presenting with STEMI were addressed later in the course of the disease with more severe left ventricular impairment. In-hospital emergency circuits and care functioned properly with no increase in door-to-balloon time and early mortality.

25 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Ciubotaru Alin FlorentinCiubotaru Alin Florentin
Ciubotaru Alin Florentin
RCRoxana Covali
Roxana Covali
CGCristina Grosu
Cristina Grosu
DADaniel Alexa
Daniel Alexa
EPEsthir Flavia Pilă
Esthir Flavia Pilă
EIEmilian Bogdan Ignat
Emilian Bogdan Ignat
Ischemic stroke remains a leading cause of mortality and disability worldwide, with current therapies such as intravenous thrombolysis and mechanical thrombectomy benefiting only a limited proportion of patients. Neuroinflammation is a key contributor to secondary brain injury, creating a strong rationale for adjunctive therapies targeting immune modulation. Fingolimod, a sphingosine-1-phosphate receptor (S1PR) modulator originally approved for multiple sclerosis, has shown promising effects in both preclinical and early clinical studies of acute ischemic stroke. Methods: We conducted a structured narrative review of preclinical and clinical studies published between 2015 and 2024, using PubMed, Scopus, and Web of Science databases. Inclusion criteria were original studies evaluating fingolimod in ischemic stroke models or human patients, either as monotherapy or in combination with reperfusion therapies. Exclusion criteria included conference abstracts without peer review, studies lacking mechanistic insight, and non-English publications. Results: Preclinical evidence demonstrates that fingolimod reduces infarct size, preserves blood–brain barrier integrity, and modulates neuroinflammation through multiple mechanisms, including T cell sequestration, microglial polarization, and mitochondrial protection. Clinical trials, though limited in size, suggest improved short- and long-term outcomes when fingolimod is used in combination with intravenous thrombolysis or endovascular therapy, with a manageable safety profile. Novel nanotechnology-based delivery systems further enhance central nervous system (CNS) targeting and reduce systemic side effects. Conclusions: Fingolimod represents a promising multi-targeted adjunctive strategy for ischemic stroke, acting at the intersection of immune modulation, vascular protection, and neuroprotection. While current findings are encouraging, larger randomized controlled trials and biomarker-driven patient selection are needed to validate its clinical utility. This review highlights the translational potential of fingolimod and outlines key directions for future research.

10 July 2025 in Medicina
Verified
Journal Article
Open access
PDF file
GSGabriela Dumachita Sargu
Gabriela Dumachita Sargu
RCRoxana Covali
Roxana Covali
CFCristiana Filip
Cristiana Filip
TBTudor Butureanu
Tudor Butureanu
MAMona Akad
Mona Akad
RPRadu Florin Popa
Radu Florin Popa
Embolic stroke of undetermined source (ESUS) was proposed in 2014 as a clinical category to subgroup non-lacunar cryptogenic ischemic strokes that appear embolic but lack an identifiable cause despite thorough investigation. The initial hypothesis was that anticoagulation might offer superior secondary prevention compared to antiplatelet therapy, prompting several large clinical trials. This review synthesizes current knowledge on ESUS. ESUS represents about 17% of ischemic strokes and often affects younger patients with fewer traditional risk factors. Although these patients lack major cardioembolic sources (e.g., atrial fibrillation) or significant arterial stenosis, many have covert embolic substrates. Major trials—NAVIGATE ESUS, RE-SPECT ESUS, and the atrial cardiopathy-focused ARCADIA—found no benefit of anticoagulants over aspirin, challenging the original ESUS framework. These results highlight the heterogeneity within ESUS and underscore the need for individualized diagnostic and therapeutic strategies.

1 June 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
GSGabriela Dumachita Sargu
Gabriela Dumachita Sargu
Razvan SocolovRazvan Socolov
Razvan Socolov
TBTeodora Ana Balan
Teodora Ana Balan
DGDumitru Gafițanu
Dumitru Gafițanu
MAMona Akad
Mona Akad
RBRaluca Balan
Raluca Balan
Struma ovarii is a rare type of ovarian teratoma primarily composed of over 50% thyroid tissue. Its occurrence is reported in 2–5% of all ovarian teratomas, with approximately 0.5% to 10% showing malignant transformation. Managing it during pregnancy poses significant challenges as pregnancy can promote the growth of malignant struma ovarii due to elevated levels of ovarian and pregnancy-related hormones, including estrogen, progesterone, and human chorionic gonadotrophin (hCG). Most ovarian tumors, including struma ovarii, are detected during routine ultrasonography in the first and second trimesters, often as acute emergencies. Diagnosis during pregnancy is rare, with some cases incidentally discovered during cesarean section when inspecting the adnexa for ovarian cysts. This review explores the diagnostic, management, and therapeutic approaches to struma ovarii during pregnancy.

1 September 2017 in The Permanente Journal
Verified
Journal Article
Closed access
RCRoxana Covali
Roxana Covali
LALucian Ambrosie
Lucian Ambrosie
MOMircea Onofriescu
Mircea Onofriescu
ALAlexandru Luca
Alexandru Luca
GSGabriela Dumachita Sargu
Gabriela Dumachita Sargu
DGDumitru Gafitanu
Dumitru Gafitanu
Roxana Covali, MD, PhD; Lucian Ambrosie, MD; Micea Onofriescu, MD, PhD; Alexandru Luca, MD, PhD; Gabriela Dumachita-Sargu, MD, PhD; Violeta Aursulesei

3 November 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
CFCatalina Filip
Catalina Filip
RCRoxana Covali
Roxana Covali
Socolov DemetraSocolov Demetra
Socolov Demetra
I(Ingrid Andrada Tanasa (Vasilache)
Ingrid Andrada Tanasa (Vasilache)
ACAlexandru Carauleanu
Alexandru Carauleanu
Razvan SocolovRazvan Socolov
Razvan Socolov
(1) Background: Thrombophilia is a tendency towards hypercoagulability, and it is increased by pregnancy, and peaking around delivery.; (2) Methods: 80 Eighty thrombophilia patients admitted for delivery between 1/10/2017 and 1/12/2021 were prospectively studied, together with 80 eighty age- and para-matched control patients. Patients were admitted for delivery at term by means of cesarean section. The inflammation indexes from the complete blood count values analysis, in during both the 24 hours before and the 24 hours after labor—, extracted from the hospital’s medical records—, were calculated, and then correlated with uterine involution.; (3) Results: In pregnant patients treated for thrombophilia patients, the patients who did not manage to have close their uterine cavity closed with in the first 24-48 hours had significantly higher SII and AISI inflammation indexes SII and AISI , than the onesthose who did manage to have their uterine cavity closed their uterine cavity. In pregnant patients treated for thrombophilia patients, MLR is higher in patients without the Rh factor than in those with the Rh factor. In non-thrombophilia patients, PLR was significantly higher as compared to treated thrombophilia patients. In non-thrombophilia patients, MCVL increased with age and, before labor, while SII and AISI increased with age, postpartum. ; (4) Conclusions: There may be an underlying inflammation state that persisted despite treatment in some pregnant thrombophilia pregnant patients.